BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34352707)

  • 1. Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms.
    Watari S; Araki M; Matsumoto J; Yoshinaga K; Sekito T; Maruyama Y; Mitsui Y; Sadahira T; Kubota R; Nishimura S; Wada K; Kobayashi Y; Takeuchi H; Tanabe K; Kitagawa M; Morinaga H; Kitamura S; Sugiyama H; Ariyoshi N; Wada J; Watanabe M; Watanabe T; Nasu Y
    Drug Metab Pharmacokinet; 2021 Oct; 40():100407. PubMed ID: 34352707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
    Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
    Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.
    Hosohata K; Masuda S; Yonezawa A; Sugimoto M; Takada Y; Kaido T; Ogura Y; Oike F; Uemoto S; Inui K
    Drug Metab Pharmacokinet; 2009; 24(5):458-63. PubMed ID: 19881258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients.
    Suzuki Y; Yoshihashi T; Takahashi K; Furuya K; Ohkohchi N; Oda T; Homma M
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients.
    Mei T; Noguchi H; Suetsugu K; Hisadome Y; Kaku K; Okabe Y; Masuda S; Nakamura M
    Biol Pharm Bull; 2020; 43(10):1600-1603. PubMed ID: 32999170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
    Miura M; Inoue K; Satoh S; Itoh Y; Kagaya H; Tada H; Tanaka Y; Habuchi T; Suzuki T
    Clin Drug Investig; 2007; 27(4):251-8. PubMed ID: 17358097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of
    Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
    Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
    Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
    Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
    J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
    Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
    J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
    Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
    Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
    Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
    Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.